(Q40406437)

20 September 2017

1 reference

title

Fibrinolysis and atherosclerosis (English)

1 reference

20 September 2017

2

1 reference

20 September 2017

1

Hamsten A

1 reference

20 September 2017

publication date

1 June 1995

1 reference

Best Practice and Research: Clinical Haematology

20 September 2017

published in

1 reference

20 September 2017

volume

8

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

345-363

1 reference

Increased fibrinolytic potential after diet intervention in healthy coronary high-risk individuals.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Weight in infancy and death from ischaemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Fetal and placental size and risk of hypertension in adult life

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Physiological consequences of loss of plasminogen activator gene function in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Plasminogen activator inhibitor in plasma is related to testosterone in men

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Fibrinolytic activity and coronary-artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Effect of treatment of hyperlipidaemia on haemostatic variables

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Raised plasma oestradiol and oestrone levels in young survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Fibrinolytic activity in men with acute myocardial infarction before 60 years of age

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Stimulation of PAI-1 expression in endothelial cells by cultured vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Fetal and infant growth and impaired glucose tolerance at age 64.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Haemostatic function in myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Lipoprotein (a) and plasminogen are immunochemically related

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Serum estrogen levels in men with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Blood coagulation and fibrinolysis in man after myocardial infarction compared with a representative population sample

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Sex hormones, insulin, lipids, and prevalent ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Lipoprotein(a), fibrin binding, and plasminogen activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Haemostatic function and cardiovascular death: early results of a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Dietary regulation of fibrinolytic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

A potential basis for the thrombotic risks associated with lipoprotein(a).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Hypertriglyceridemia and regulation of fibrinolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Evidence for hyperoestrogenaemia as a risk factor for myocardial infarction in men

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

The association of hypotestosteronemia with coronary artery disease in men

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Fibrinolytic capacity of arm and leg veins after femoral shaft fracture and acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Endogenous tissue-type plasminogen activator and risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Hypertriglyceridaemia and hypercoagulability

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Role of endothelium in sequestration of lipoprotein and firbrinogen in aortic lesions, thrombi, and graft pseudo-intimas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

The effect of body build, diet and endocrine factors on the extrinsic fibrinolytic system in healthy young women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

INSULIN DEFICIENCY IN NON-INSULIN-DEPENDENT DIABETES

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Disordered "fibrinolytic potential" in coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Impaired fibrinolysis and risk of thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

Circulating proinsulin-like molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980272-0

7 January 2021

10.1016/S0950-3536(05)80272-0

Identifiers

DOI

1 reference

20 September 2017

1 reference